Dover has entered right into a definitive agreement to accumulate Malema Engineering Corp, a US designer and manufacturer of high-precision, mission-critical flow-measurement and control devices for the biopharmaceutical, semiconductor and industrial sectors.
Malema’s merchandise will expand Dover’s biopharma single-use production offering, which already contains Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with amenities in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in income in the course of the full 12 months 2022.
When the deal closes, Malema will turn into part of the PSG enterprise unit within Dover’s Pumps & Process Solutions phase.
“We see an amazing long-term growth alternative within the bioprocessing trade driven by a powerful and growing pipeline of effective novel biologic medication, biosimilars, protein therapies, non-COVID mRNA vaccines, in addition to budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the growing adoption of more efficient single-use production processes supports a strong outlook for our choices of single-use parts to end-customers. We imagine that pairing Malema’s know-how with our existing portfolio of single-use pumps for biopharma processing will significantly enhance the accuracy and value proposition of our options to our customers.”
“We are methodically building out our biopharma platform through proactive capability additions, new product growth, and opportunistic acquisitions of highly-attractive niche part applied sciences,” stated Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing technology and additional strengthens our sensor portfolio with new proprietary know-how. In เกจวัดแรงดันไอน้ำ to attractive biopharma purposes, we count on sturdy development in the semiconductor space on the capability growth and re-shoring tailwinds.”
Share